Press releaseBusiness Wire
enGene Therapeutics
ENGNW · NASDAQ
$0.2299+$0.04 (+21.06%)TodayMarket closed ·
Prev close $0.1899
ENGNW key statistics
- Market cap
- —
- Price-earnings ratio
- 0.00
- Dividend yield
- —
- Average volume
- 9.79K
- Volume
- 2.66K
- Open price
- $0.2087
- High today
- $0.2399
- Low today
- $0.20
- 52 Week high
- $4.20
- 52 Week low
- $0.1113
enGene Therapeutics (ENGNW) at a glance
enGene Therapeutics (ENGNW) last traded at $0.2299, with a price-to-earnings ratio of 0.00.
Today the stock has traded between $0.20 and $0.2399. The current price is 14.9% above the day's low and 4.2% below its high.
Volume so far is 2.66K shares, below the average of 9.79K shares a day.
Over the past year enGene Therapeutics has ranged from $0.1113 to $4.20, and now sits 3% of the way up that range.
ENGNW news
Most active stocks
Highest trading volume today
- EARIEntertainment Arts Research$0.0002+0.00%
- GTVHGolden Triangle Ventures$0.0002+100.00%
- TMSHTrans Global Assets$0.0003+20.00%
- RDARRaadr$0.0002+0.00%
- GPUSHyperscale Data$0.1689+34.05%
- SEIISharing Economy International$0.0002−33.33%
- ELMEElme Communities$1.77+0.57%
- SHFSSHF Holdings$0.1324−61.39%
- XXII22nd Century Group$0.1977−8.34%
- NBNDNetBrands$0.0006−40.00%
- NVDGraniteShares ETF Trust$4.19+0.96%
- HIRUHiru$0.0006+9.09%
Newly listed
Companies that went public in the past six weeks
- TCXBTCGX Acquisition Corp. II$10.49−0.10%
- CTYCITY THERAPEUTICS$20.77+0.00%
- IAMIambic Therapeutics$14.26−2.79%
- AMROAmaero$5.84+7.75%
- FLSCFrazier Life Sciences Acquisition Corp. II$10.30+0.29%
- TRXBTRex Bio$13.81−10.90%
- RTSNRetension Pharmaceuticals$15.25−1.61%
- PAXGUPine Tree Acquisition$10.01+0.05%
- PORTUSouthport Acquisition Corp. IIListed Oct 1, 2026
- CHWMChilwa Minerals$5.13−0.77%
- ACCVAccelevation Holdings$12.38+1.06%
- RZAIROZE AI$10.92−1.89%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.